Xenetic Biosciences (NASDAQ:XBIO) Issues Quarterly Earnings Results, Misses Expectations By $0.48 EPS

Xenetic Biosciences (NASDAQ:XBIO) released its quarterly earnings results on Tuesday. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.48), Zacks reports. Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 49.51%.

Xenetic Biosciences Trading Down 5.7 %

Xenetic Biosciences stock traded down $0.21 on Tuesday, hitting $3.46. 13,751 shares of the stock traded hands, compared to its average volume of 12,669. The firm has a market cap of $5.34 million, a P/E ratio of -1.30 and a beta of 2.17. The business’s fifty day simple moving average is $4.03 and its 200 day simple moving average is $4.01. Xenetic Biosciences has a 1 year low of $2.78 and a 1 year high of $5.20.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “neutral” rating on shares of Xenetic Biosciences in a report on Thursday, December 5th.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.